Analyse produit facultative
Avec votre autorisation, nous utilisons une analyse limitée et respectueuse de la vie privée pour comprendre les parcours de recherche utiles. Nous n’utilisons ni traceurs publicitaires ni enregistrement de session. Vous pouvez modifier ce choix dans les préférences. Consultez la Politique de confidentialité.
Morgan Stanley's published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $318.2B | |
|---|---|---|
| Revenue (ttm) | 79.8B | |
| Net income (ttm) | 19.8B | |
| EPS (ttm) | $12.6 | |
| Shares out | 1.6B | |
| P/E (trailing) | 15.1x | |
| P/E (forward) | 15.1x | |
| Dividend | $4.60 (2.42%) | |
| Volume | 4,185,694 | |
| Beta | 1.21 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $57.78B | $62.48B | $88.29B | $103.15B | $114.98B | +18.8% |
| Gross profit | $56.41B | $49.93B | $50.14B | $57.36B | $65.62B | +3.9% |
| Operating income | $19.67B | $14.09B | $11.81B | $17.60B | $21.95B | +2.8% |
| Net income | $15.03B | $11.03B | $9.09B | $13.39B | $16.86B | +2.9% |
| EPS (diluted) | $8.03 | $6.15 | $5.18 | $7.95 | $10.21 | +6.2% |
| EBITDA | $23.88B | $18.09B | $16.07B | $22.76B | $26.61B | +2.7% |
| R&D | — | — | — | — | — | — |
| SG&A | $24.63B | $23.05B | $24.21B | $26.18B | $29.07B | +4.2% |
Recent company headlines from major financial publishers.
The Base scenario targets $119.68 with a probability of 55.0%, implying an expected return of -41.9% from $206.12. This path assumes steady wealth fee growth and normalized institutional trading revenues. Disconfirmation would occur if underwriting dealflow stalls or advisory margins compress over coming quarters.
The Bull scenario targets $155.02 with a probability of 20.0%, offering an expected return of -24.8% from $206.12. This outcome requires surging corporate capital expenditures and an active IPO calendar driving strong institutional operating leverage. Disconfirmation would emerge if corporate financing bypasses traditional syndicates into direct private deals.
| Ke ↓ / g → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 7.8% | $132 | $133 | $135 | $137 | $140 |
| 8.8% | $124 | $125 | $127 | $128 | $130 |
| 9.8% | $118 | $119 | $120 | $121 | $122 |
| 10.8% | $112 | $113 | $114 | $114 | $115 |
| 11.8% | $107 | $108 | $108 | $109 | $109 |
Upcoming earnings date and setup when available.
La notation portée par l'édition de recherche publiée chaque mois. Une notation compare le cours à la date d'analyse à la juste valeur ; elle n'indique pas si l'appréciation s'est révélée juste.
| Année | janv. | févr. | mars | avr. | mai | juin | juil. | août | sept. | oct. | nov. | déc. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
